Date of Award

2015

Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant

Department

Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C

Abstract

Objective: The objective of this selective EBM review is to determine whether or not Lurasidone is more safe and effective in the treatment of schizoaffective disorder and schizophrenia than other common anti-psychotic medications. Study Design: Review of two English language randomized double-blinded controlled comparisons and one English language Randomized open-label parallel-group comparison. Data Sources: The randomized double-blinded controlled comparison studies and the randomized open-label parallel-group comparison were all found using PubMed and EBSCOhost databases. All three articles were published in peer-reviewed journals. Outcomes Measured: Participant withdrawal due to adverse effects and treatment failure, patient responses to MATRICS consensus cognitive battery, interview responses, and patient responses on the schizophrenia cognition rating scale were all measured to determine the efficacy and safety of Lurasidone. Results: According to Harvey et. al, the difference between Lurasidone and other common anti-psychotics, such as Ziprasidone, is not statistically significant with a p= 0.058. Potkin, et. al reported that Lurasidone is more safe and effective compared to other common anti-psychotics with a p= 0.020. McEvoy et. al demonstrated the safety and efficacy of lurasidone with p values <0.05. Conclusion: The results from this review are inconclusive. One study with a p value of 0.020 and another with p values <0.05 indicates that Lurasidone is more safe and effective and, but a p value of 0.058 in the third study does not agree with the findings of the other studies.

Download

Share

COinS